Stuart J. Gallagher

Stuart J. Gallagher

Missenden Road
Camperdown, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: June 25, 2026

BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.

BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.

Journal: Pigment cell & melanoma research

Published: December 18, 2023

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.

Journal: The Journal of investigative dermatology

Published: June 22, 2021

Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.

Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.

Journal: Pathology

Published: December 21, 2020

Sex bias of females in survival from cancer and infections. Is X the answer?

Sex bias of females in survival from cancer and infections. Is X the answer?

Journal: British journal of cancer

Published: November 12, 2020

A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.

A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.

Journal: The Journal of investigative dermatology

Published: October 01, 2020

Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.

Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.

Journal: Cancers

Published: June 26, 2020

Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?

Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?

Journal: Pigment cell & melanoma research

Published: November 27, 2019

Shedding light on dabrafenib-induced fevers in patients with melanoma.

Shedding light on dabrafenib-induced fevers in patients with melanoma.

Journal: The Lancet. Oncology

Published: September 19, 2019

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.

Journal: The Journal of investigative dermatology

Published: September 13, 2019

Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.

Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.

Journal: International journal of cancer

Published: August 22, 2019

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.

Journal: International journal of oncology

Published: August 22, 2019

Showing 1-12 of 38

Last Updated: 09/26/2026